$3.84
15.51% today
Nasdaq, Nov 04, 09:17 pm CET
ISIN
US98943L1070
Symbol
ZNTL
Sector
Industry

Zentalis Pharmaceuticals Inc Target price 2024 - Analyst rating & recommendation

Zentalis Pharmaceuticals Inc Classifications & Recommendation:

Buy
44%
Hold
56%

Zentalis Pharmaceuticals Inc Price Target

Target Price $11.00
Price $3.32
Potential
Number of Estimates 8
8 Analysts have issued a price target Zentalis Pharmaceuticals Inc 2025 . The average Zentalis Pharmaceuticals Inc target price is $11.00. This is higher than the current stock price. The highest price target is , the lowest is .
A rating was issued by 9 analysts: 4 Analysts recommend Zentalis Pharmaceuticals Inc to buy, 5 to hold and 0 to sell.
Analysts don't have a crystal ball either, but they do represent the opinion of the market quite well. You should not take the price potential and the ratings as a recommendation to act. Rather, they serve as an additional building block for your own opinion or stock analysis.
Analyst Estimates: Analysts believe that the Zentalis Pharmaceuticals Inc stock has an average upside potential 2025 of . Most analysts recommend the Zentalis Pharmaceuticals Inc stock at Hold.

Sales and Margin forecast 2024, 2025 to 2028

Create a premium account to unlock analyst estimates. Learn more

Quarter Annually
Dec '23 2024
Estimates
Revenue Million $ 0.00 40.63

9 Analysts have issued a sales forecast Zentalis Pharmaceuticals Inc 2024 . The average Zentalis Pharmaceuticals Inc sales estimate is

$40.6m
Unlock
. This is
0.16% higher
Unlock
than the revenue of the last 12 months(TTM). The highest sales forecast is
$41.0m 1.08%
Unlock
, the lowest is
$40.6m 0.00%
Unlock
.

This results in the following potential growth metrics:

Revenue Estimates

2023 $0.0
2025
$0.0 100.00%
Unlock
2027
$29.1m 10.70%
Unlock
2028
$120m 312.75%
Unlock

1 Analyst has issued an EBITDA forecast Zentalis Pharmaceuticals Inc 2024 . The average Zentalis Pharmaceuticals Inc EBITDA estimate is

$-229m
Unlock
. This is
4.39% lower
Unlock
than the EBITDA of the last 12 months(TTM). The highest EBITDA forecast is
$-229m 4.39%
Unlock
, the lowest is
$-229m 4.39%
Unlock
.

This results in the following potential growth metrics and future EBITDA Margins:

EBITDA Estimates

2023 $-253m 11.82%
2024
$-229m 9.39%
Unlock
2025
$-278m 21.65%
Unlock
2026
$-286m 2.73%
Unlock

EBITDA Margin

9 Zentalis Pharmaceuticals Inc Analysts have issued a net profit forecast 2024. The average Zentalis Pharmaceuticals Inc net profit estimate is

$-213m
Unlock
. This is
8.97% lower
Unlock
than the net profit for the last 12 months(TTM). The highest net profit forecast is
$-201m 2.55%
Unlock
, the lowest is
$-224m 14.55%
Unlock
.

This results in the following potential growth metrics and future Net Margins:

Net Profit Estimates

2023 $-318m 0.22%
2024
$-213m 32.96%
Unlock
2025
$-254m 19.17%
Unlock
2026
$-236m 7.19%
Unlock
2027
$-212m 10.24%
Unlock
2028
$-119m 43.80%
Unlock

Net Margin

2027
-726.58% 18.91%
Unlock
2028
-98.93% 86.38%
Unlock

Earnings per share, P/E ratio and EV/sales Estimates 2024, 2025 to 2028

Create a premium account to unlock analyst estimates. Learn more

Quarter Annually
Dec '23 2024
Estimates
Earnings Per Share $ -4.47 -3.00
0.22% 32.89%
P/E negative
EV/Sales negative

9 Analysts have issued a Zentalis Pharmaceuticals Inc forecast for earnings per share. The average Zentalis Pharmaceuticals Inc <a href=https://blog.stocksguide.com/knowledge/eps-simply-explained>EPS is

$-3.00
Unlock
. This is
9.09% lower
Unlock
than earnings per share in the financial year 2023. The highest <a href=https://blog.stocksguide.com/knowledge/eps-simply-explained>EPS forecast is
$-2.82 2.55%
Unlock
, the lowest is
$-3.15 14.55%
Unlock
.

This results in the following potential growth metrics and future valuations:

Earnings Per Share

2023 $-4.47 0.22%
2024
$-3.00 32.89%
Unlock
2025
$-3.57 19.00%
Unlock
2026
$-3.31 7.28%
Unlock
2027
$-2.98 9.97%
Unlock
2028
$-1.67 43.96%
Unlock

P/E ratio

Current -1.21 64.09%
2024
-1.11 8.26%
Unlock
2025
-0.93 16.22%
Unlock
2026
-1.00 7.53%
Unlock
2027
-1.12 12.00%
Unlock
2028
-1.99 77.68%
Unlock

Based on analysts' sales estimates for 2024, the Zentalis Pharmaceuticals Inc stock is valued at an <a href=https://blog.stocksguide.com/knowledge/enterprise-value-sales-simply-explained>EV/Sales of

-3.60
Unlock
and an <a href=https://blog.stocksguide.com/knowledge/price-sales-ratio-simply-explained>P/S ratio of .

This results in the following potential growth metrics and future valuations:

EV/Sales

Current -3.61
2024
-3.60 0.26%
Unlock
2027
-5.02 9.66%
Unlock
2028
-1.22 75.77%
Unlock

P/S ratio

Current
2024
5.81 0.16%
Unlock
2027
8.11 9.66%
Unlock
2028
1.96 75.77%
Unlock

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today